Stay updated on Daratumumab & DLI for Relapsed AML Clinical Trial
Sign up to get notified when there's something new on the Daratumumab & DLI for Relapsed AML Clinical Trial page.

Latest updates to the Daratumumab & DLI for Relapsed AML Clinical Trial page
- Check7 days agoChange DetectedThe page's revision tag was updated to v3.5.4, indicating a new software revision was applied. The previous revision v3.5.3 was removed.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedThe page’s release/version marker was updated from “Revision: v3.5.2” to “Revision: v3.5.3,” indicating a ClinicalTrials.gov site revision without changing the underlying study details.SummaryDifference0.1%

- Check36 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2; no user-facing content changes are evident.SummaryDifference0.1%

- Check65 days agoChange DetectedRevision history updated: added Revision: v3.5.0 and removed Revision: v3.4.3.SummaryDifference0.1%

- Check79 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.1%

- Check101 days agoChange DetectedA minor site version update from v3.4.1 to v3.4.2 with no visible changes to the study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Daratumumab & DLI for Relapsed AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab & DLI for Relapsed AML Clinical Trial page.